Lung Cancer | Specialty

Early Activity Observed With Capmatinib in Advanced NSCLC

September 28th 2016

The c-MET inhibitor capmatinib (INC280) demonstrated early signals of efficacy with an overall response rate of 20% when administered to patients with advanced c-MET–dysregulated non–small cell lung cancer.

Dr. Neal on Exciting Advancements in the Field of Lung Cancer

September 28th 2016

Joel Neal, MD, PhD, assistant professor of Medicine (Oncology), Stanford University Medical Center, discusses exciting advancements in the field of lung cancer over the past few years.

Dr. Gaspar on a Physician Survey on Prophylactic Cranial Irradiation in SCLC

September 28th 2016

Laurie E. Gaspar, MD, professor, Radiation Oncology, University of Colorado Denver, discusses a survey she conducted for physicians on the use of prophylactic cranial irradiation for patients with limited small cell lung cancer.

Dr. Wakelee on BIRCH Trial for Atezolizumab in Patients With NSCLC

September 24th 2016

Heather A. Wakelee, MD, associate professor of Medicine (Oncology), Stanford University Medical Center, regent, International Association for the Study of Lung Cancer (IASLC) discusses updated efficacy findings from the BIRCH trial, which was a phase II study of atezolizumab (Tecentriq) for patients with PD-L1–selected advanced non–small cell lung cancer (NSCLC). Wakelee discussed these findings during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. Hirsch on Value of PD-L1 Testing in Patients With Lung Cancer

September 23rd 2016

Fred R. Hirsch, MD, PhD, professor of Medicine, University of Colorado Denver, CEO, the International Association for the Study of Lung Cancer (IASLC), discusses the value of PD-L1 assays for patients with non–small cell lung cancer. Hirsch shared his during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. Harvey I. Pass on Personalized Surgical Approaches in Lung Cancer

September 23rd 2016

Harvey I. Pass, MD, director, Thoracic Surgery, Thoracic Oncology, NYU Langone Medical Center, discusses what it means to take a personalized approach to surgery in lung cancer.

Frontline Ceritinib Delays Progression in ALK+ NSCLC

September 23rd 2016

Ceritinib improved progression-free survival compared with standard chemotherapy as a first-line treatment for patients with ALK-positive non–small cell lung cancer.

Dr. Gandara on How Lung-MAP Trial is Optimal for Patient Care

September 23rd 2016

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), discusses the Lung Master Protocol (Lung-MAP) Trial and how it is an example of a rational clinical design that will impact patient care. Gandara shared this insight during an interview at the 2016 IASLC Multidisciplinary Symposium on Thoracic Oncology.

Dr. David L. Rimm on Alternatives to PD-L1 to Predict Immunotherapy Response in Lung Cancer

September 22nd 2016

Dr. Jett on Debates on Molecular Testing for Lung Cancer

September 21st 2016

James R. Jett, MD, professor of Medicine Emeritus, National Jewish Health, discusses the most frequent debates surrounding molecular testing for patients with lung cancer.

Dr. Kelly on the Toxicity Profile in CheckMate-227 in NSCLC

September 20th 2016

Karen Kelly, MD, associate director for Clinical Research, Jennifer Rene Harmon Tegley and Elizabeth Erica Harmon Endowed Chair in Cancer Clinical Research, professor of Medicine, UC Davis Comprehensive Cancer Center, UC Davis Health System, discusses the toxicity profile of the therapies used in the CheckMate-227 trial.

Rizvi Recounts Recent Immunotherapy Advances in Lung Cancer

September 20th 2016

Naiyer Rizvi, MD, discusses pivotal clinical trials of immunotherapy agents for patients with lung cancer and expresses his optimism regarding the treatment for the field.

Leading Researchers Dissect PD-1/PD-L1 Evidence in NSCLC

September 15th 2016

Although lung cancer remains the leading cause of cancer-related mortality in the United States and 5-year survival rates are low at 17.8%, the grim picture for this tumor type is starting to shift to a more hopeful one as its biology is becoming better understood, facilitating treatment selection and providing researchers with new therapeutic targets.

Dr. Hak Choy on Radiation and Immunotherapy in Combination in Lung Cancer

September 15th 2016

Dr. Riess on ROS1 Fusions in Lung Cancer

September 14th 2016

Jonathan Riess, MD, assistant professor of Medicine, Division of Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses ROS1 fusions in lung cancer.

Dr. Kim on Combination Therapies in Lung Cancer

September 13th 2016

Edward S. Kim, MD, chair, Solid Tumor Oncology and Investigational Therapeutics, Donald S. Kim Distinguished Chair for Cancer Research, Levine Cancer Institute, Carolinas HealthCare System, discusses combination therapies in the treatment of patients with lung cancer.

Dr. Stevenson on Potential of Immunotherapy in Squamous NSCLC

September 8th 2016

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

Dr. Decker on Stereotactic Body Radiation Therapy in Lung Cancer

September 8th 2016

Roy Decker, MD, PhD, associate professor of Therapeutic Radiology, Yale Cancer Center, discusses stereotactic body radiation therapy (SBRT) as a treatment for patients with lung cancer.

FDA Grants Pembrolizumab Priority Review in Frontline NSCLC

September 7th 2016

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab (Keytruda) as a first-line treatment for patients with PD-L1–positive non–small cell lung cancer.

A Man With Many Mentors Makes His Own Mark in Lung Cancer

September 4th 2016

John D. Minna, MD, who helped establish the first tumor lines and discover the c-Myc oncogene in lung cancer, was honored in the Lung Cancer category with a 2015 Giants of Cancer Care award, a program that OncLive launched to recognize leaders in the field.